CAS: 1258226-87-7; Methyl ((S)-1-((S)-2-((4-((2S,5S)-1-(4-(Tert-Butyl)Phenyl)-5-(4-((S)-1-((Methoxycarbonyl)-L-Valyl)Pyrrolidine-2-Carboxamido)Phenyl)Pyrrolidin-2-yl)Phenyl)Carbamoyl)Pyrrolidin-1-yl)-3-Methyl-1-Oxobutan-2-yl)Carbamate

该化合物是一种被归类为NS5A抑制剂的直接作用抗病毒剂,主要用于治疗慢性丙型肝炎病毒(HCV)感染,它展示了针对HCV基因型1的有力活动,并经常与其他抗病毒剂,如Paritaprevir和Ritonavir结合,以提高功效和减少抗药性的发展.Ombitasvir通过抑制NS5A蛋白干扰病毒复制,该蛋白对病毒性RNA合成和组装至关重要.它由于在混合疗法中阻力和协同效应的极大障碍,因此成为HCV治疗疗程中有价值的成分.该化合物的特点是其有利的药用植物特征和选择性行动机制.

结构式图片

上下游产品

4,4'-[(2S,5S)-1-[4-(1,1-二甲基乙基)苯基]-2,5-吡咯烷二基]二-苯胺 4,4'-((2S,5S)-1-(4-Tert-Butylphenyl)Pyrrolidine-2,5-Diyl)Dianiline 1258235-06-1
(S,S)-1-(2-Methoxycarbonylamino-3-Methylbutyryl)Pyrrolidine-2-Carboxylic Acid Benzyl Ester 1258232-91-5

合成工艺路线路线简述

    Moc-L-缬氨酸置于三乙胺,N,N-二异丙基乙胺,Methanaminium,N-[(Dimethylamino)(3H-1,2,3-Triazolo[4,5-B]Pyridin-3-Yloxy)Methylene]-N-Methyl-,Hexafluorophosphate(1-),N,N'-二异丙基碳二亚胺体系中,用 水,乙酸乙酯,N,N-二甲基甲酰胺,乙腈 用作溶剂,化学反应 2.5H,反应生成翁比他韦
    参考文献: Anti-Viral Compound[fr] Composé Antiviral
    标题: Anti-Viral Compound[fr] Composé Antiviral
    摘要:本发明涉及化合物i的晶体形式.

    专利信息


    专利号:US-6683189-B1
    优先权日:1996-02-26
    标 题 :Method for the synthesis of pyrrole and imidazole carboxamides on a solid support
    发明人:DERVAN PETER B; BAIRD ELDON
    权利人:CALIFORNIA INST OF TECHN
    摘要:The present invention describes a novel method for the solid phase synthesis of polyamides containing imidazole and pyrrole carboxamides. The polyamides are prepared on a solid support from aromatic carboxylic acids and aromatic amines with high stepwise coupling yields (>99%), providing milligram quantities of highly pure polyamides. The present invention also describes the synthesis of analogs of the natural products Netropsin and Distamycin A, two antiviral antibiotics. The present invention also describes a novel method for the solid phase synthesis of imidazole and pyrrole carboxamide polyamide-oligonucleotide conjugates. This methodology will greatly increase both the complexity and quantity of minor-groove binding polyamides and minor-groove binding polyamide-oligonucleotide conjugates which can be synthesized and tested.

    专利号:US-2018297925-A1
    优先权日:2015-10-12
    标题 :Methods for total synthesis of resolvin e1
    发明人:JAGTAP PRAKASH
    权利人:SALZMAN LOVELACE INVEST LTD
    摘要:Methods for total chemical synthesis of Resolvin E1 (RvE1) include Wittig reaction of two compounds having hydroxyl protecting group in the presence of a strong base, removal of the hydroxyl-protecting groups with a deprotecting reagent to produce a compound having an ester group, and hydrolysis of the ester group to obtain RvE1

    专利号:US-6271379-B1
    优先权日:2000-03-08
    标题:Intermediates useful for the synthesis of huperzine A
    发明人:TUECKMANTEL WERNER; KOZIKOWSKI ALAN P
    权利人:UNIV GEORGETOWN
    摘要:Intermediates useful for the synthesis of huperzine A represented by the structures below, n and methods for their synthesis, wherein: n R 1 is lower alkyl, benzyl, or substituted benzyl; n X is a suitable leaving group; n Y is an electron withdrawing group that can subsequently be converted into an amino group; n one broken line is present as a carbon—carbon bond and the other broken line is absent, where the broken line forms an unconjugated carbon—carbon double bond, which double bond may be endocyclic whereby n is 3 or the double bond may be exocyclic whereby n is 2.

    专利号:US-6262251-B1
    优先权日:1995-10-19
    标题 :Method for solution phase synthesis of oligonucleotides
    发明人:PIEKEN WOLFGANG; MCGEE DANNY; SETTLE ALECIA; ZHAI YANSHENG; HUANG JIANPING
    权利人:PROLIGO LLC
    摘要:This invention discloses an improved method for the sequential solution phase synthesis of oligonucleotides. The method lends itself to automation and is ideally suited for large scale manufacture of oligonucleotides with high efficiency.

    专利号:US-6133409-A
    优先权日:1996-12-19
    标 题:Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
    发明人:SALVINO JOSEPH M; MORTON GEORGE C; MASON HELEN J; LABAUDINIERE RICHARD F
    权利人:AVENTIS PHARM PROD INC
    摘要:This invention is directed to a process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha , beta -unsaturated carboxylic acid and aldehyde compounds and to polymeric hydroxylamine resin compounds useful therefor.

    专利号:US-5808019-A
    优先权日:1994-12-19
    标题 :Intermediate compounds for the synthesis of glycolipids
    发明人:HASEGAWA AKIRA; KISO MAKOTO; ISOGAI YUKIHIRO; KITAMURA SEIICHI; UEDA HIROSHI
    权利人:TOA BOSHOKU KABUSHIKI KAISHA
    摘要:The invention provides important intermediate compounds for the synthesis of acidic glycolipids which are identical with the glycolipid antigens isolated from the acidic glycolipid fractions of peripheral nerve and embryonic central nervous system and preparation methods thereof. By the adoption of the present intermediate compounds, sulfation of 3-hydroxyl group of end glucuronic acid portion of the acidic glycolipid can be quite easily carried out and total synthetic yield be greatly improved.
    杭州杜易科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.deasypharma.com
    企业联系电话:0571-86182782👤
    📞杭州杜易科技有限公司 ⚠️参考联系方式
    联系人:宋女士
    电话:0571-86182782
    手机:15397199029
    传真:0571-89057225
    邮箱:songxy@deasypharma.com
    通信地址: 杭州市余杭区龙潭路16号1幢北4层
    邮编: 311121
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:杭州市余杭区龙潭路16号1幢北4层
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    台州市科瑞生物技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.pharm-intermediates.com
    企业联系电话:0576-88813233👤
    📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
    联系人:金崇光
    电话:0576-88813233
    手机:13396860566
    传真:0576-88813233
    邮箱:sales@pharm-intermediates.com
    通信地址: 台州市开发大道东段288号
    邮编: 318000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:台州市开发大道东段288号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    杭州拜善晟生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.bsaz.com
    电话: 0571-28111272 18505711187👤
    📞杭州拜善晟生物科技有限公司 ⚠️参考联系方式

    销售电话:0571-28111272 18505711187
    邮箱:peter@bsaz.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Miura M, Nishino M, Kawaguchi K, Li S, Shimakami T, Tamai T, Nakagawa H, Terashima T, Iida N, Takatori H, Arai K, Sakai Y, Yamashita T, Honda M, Kaneko S, Mizukoshi E, Yamashita T. Programmed cell death-1 is involved with peripheral blood immune cell profiles in patients with hepatitis C virus antiviral therapy. PLoS One. 2024 May 23;19(5):e0299424. doi: 10.1371/journal.pone.0299424.
    2: Moon C, Porges E, Roberts A, Bacon J. A combination of nirmatrelvir and ombitasvir boosts inhibition of SARS-CoV-2 replication. Antiviral Res. 2024 May;225:105859. doi: 10.1016/j.antiviral.2024.105859. Epub 2024 Mar 14. 169(3):45. doi: 10.1007/s00705-024-05990-z. 257(Pt 2):128672. doi: 10.1016/j.ijbiomac.2023.128672. Epub 2023 Dec 11.
    11:1179531. doi: 10.3389/fpubh.2023.1179531.

    合成参考文献


    参考文献:10.1007/s40265-014-0232-6
    摘要:Bichoupan K, Dieterich DT. Hepatitis C in HIV-infected patients: impact of direct-acting antivirals. Drugs. 2014 Jun;74(9):951–61. doi: 10.1007/s40265-014-0232-6.
    参考文献:10.1128/aac.01778-15
    摘要:Badri PS, Dutta S, Wang H, Podsadecki TJ, Polepally AR, Khatri A, Zha J, Chiu YL, Awni WM, Menon RM. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir. Antimicrob Agents Chemother. 2016 Jan;60(1):105–14.
    参考文献:10.1016/j.jhep.2015.10.005
    摘要:Feld JJ, Moreno C, Trinh R, Tam E, Bourgeois S, Horsmans Y, Elkhashab M, Bernstein DE, Younes Z, Reindollar RW, Larsen L, Fu B, Howieson K, Polepally AR, Pangerl A, Shulman NS, Poordad F. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016 Feb;64(2):301–7. doi: 10.1016/j.jhep.2015.10.005.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知